USFDA gives nod for Granules’ generic BP drug

December 28, 2021 11:00 pm | Updated 11:00 pm IST - HYDERABAD

Drugmaker Granules has received US Food and Drug Administration approval for a generic version of Prazosin Hydrochloride Capsules, a drug indicated in the treatment of hypertension (high blood pressure).

Bioequivalent to the reference listed drug, Mini plus capsules 1mg, 2mg and 5mg of Pfizer Inc, the approved product would be available for the U.S market shortly, Granules India said on USFDA approving the ANDA of subsidiary Granules Pharmaceuticals Inc. (GPI).

The current annual U.S. market for Prazosin Hydrochloride 1mg, 2mg, 5mg strengths is approximately $54 million, the company said in a release citing IQVIA/IMS Health numbers.

GPI executive director Priyanka Chigurupati said the product “will surely be a valuable addition to our growing product portfolio in the U.S. market.” Granules now has 46 ANDA approvals from USFDA (44 final approvals and two tentative approvals).

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.